Can-Fite Biopharma shares are trading higher after the company announced namodenoson was granted FDA orphan drug designation status for pancreatic cancer.
Portfolio Pulse from Benzinga Newsdesk
Can-Fite Biopharma's shares rose following the FDA's orphan drug designation for its drug namodenoson, aimed at treating pancreatic cancer.
October 09, 2024 | 12:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Can-Fite Biopharma's stock price increased after the FDA granted orphan drug designation to its drug namodenoson for pancreatic cancer, potentially enhancing its market exclusivity and development support.
The FDA's orphan drug designation is a significant regulatory milestone that can lead to market exclusivity and financial incentives, likely boosting investor confidence and driving up the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100